Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins
Biogen said Thursday it has wrapped up its purchase of Apellis Pharmaceuticals, bringing Apellis under its wing as a fully owned subsidiary. The deal takes Apellis off the Nasdaq as an independent biotech, and hands Biogen ownership of its two approved drugs, which join Biogen’s rare-disease division.